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Althoughthecharacteristicsandsafetyofradiocontrastmediainperitonealdialysis(PD)patientsarenotyetwelldeﬁned,theiruse
in PD patients is considered generally safe. In this study, we evaluated clearance and adverse events of iopamidol in PD patients.
We measured the iopamidol concentration in the plasma, dialysate, and urine of 11 patients. Iopamidol clearance from patient
plasma was delayed with a half-life of 33.3h, and the elimination ratio was 83.6% for 96h. We retrospectively investigated adverse
events occurring in a total of 50 stable PD patients who underwent a total of 64 angiographic computed tomography (CT) scans.
In 64 angiographic CT scans, two cases of adverse events were observed. Our results suggest that iopamidol can be eliminated by
regular PD and careful observation for adverse events are necessary for the safe use of radiocontrast media.
1.Introduction
With the increased incidence of chronic renal failure, radio-
contrast studies are important for diagnosis and treatment.
Therefore, the use of iodinated radiocontrast media in com-
puted tomography (CT) and angiography is often required
in these patients [1–3]. The European Society for Urogenital
Radiology guidelines, which were published in 1999, did not
recommend hemodialysis (HD) after the use of iodinated
radiocontrast media in continuous ambulatory peritoneal
dialysis (CAPD) patients [4–6] .H o w e v e r ,af e ws t u d i e sh a v e
addressed the peritoneal clearance and safety of iodinated
radiocontrast media in CAPD patients [7–9]. Peritoneal
dialysis (PD) is eﬀective for removing iodinated radiocon-
trast media from the body, but it takes longer time than
HD. The accumulation or delayed elimination of iodinated
radiocontrastmediamaycauseadverseeventsinchronicdia-
lysis patients with anuria or cardiovascular dysfunction.
Several reports have demonstrated acute adverse events such
as heat sensations, acute urticaria, and iododerma, and dela-
yed reactions such as vasculitis, skin disorders, submandibu-
lar swelling, and sialoadenitis even with the use of low
osmolarnonioniccontrastmedia[2,7,10–13].However,not
much is known about the adverse events caused by delayed
elimination.Inthisstudy,weevaluatedtheclearanceofiopa-
midol, a low osmolar nonionic iodinated radiocontrast
media, and the incidence of adverse events associated with
its use in CAPD patients.
2.SubjectsandMethods
Between 2002 and 2009, 50 patients who had undergone a
total of 64 angiographic CT scans while receiving CAPD at
the Akita City Hospital and the Oyokyo Kidney Research2 International Journal of Nephrology
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Figure 1:Patientclassiﬁcation.Forty-fourpatientswhounderwentatotalof58angiographicCTscanswereenrolledinthenonhemodialysis
(non-HD) group, and six patients with a total of six angiographic CT scans were enrolled in the immediate HD group. Eleven patients in the
non-HD group who participated in the clearance of iopamidol analysis.
Table 1: Patient characteristics. Patients were divided into two gro-
ups: nonhemodialysis (non-HD) group and the immediate HD
group. Crea: serum creatinine, eGFR: estimated glomerular ﬁltra-
tion rate.
Patient’s characteristics All non-HD immediate HD
n 50 44 6
Angiographic CT (times) 64 58 6
Age 55.0 ± 13.1 54.9 ± 13.2 55.8 ± 9.8
Gender (M/F) 34/16 30/14 5/1
Diabetes mellitus (+/−) 11/39 11/33 0/6
Dialysis duration (M) 58.4 ± 44.1 58.6 ± 43.5 72.1 ± 52.1
Dialysate (L/day) 8.84 ± 1.54 8.90 ± 1.58 8.40 ± 0.89
Urine volume (mL/day) 117 ± 183 119 ± 186 78.1 ± 127
Crea (mg/dL) 11.2 ± 3.2 11.1 ± 3.3 11.4 ± 2.5
eGFR (mL/min/1.73m2)4 . 5 0 ± 1.7 4.60 ± 1.8 4.00 ± 0.7
Iopamidol (mL/body) 82.0 ± 24.0 80.2 ± 24.7 100 ± 0.00
Institute were enrolled in the study (Figure 1). Patients had
been stabilized on CAPD for more than 6 months at the
time of the study. All patients received 1.75- to 2.75-L
bags, with glucose concentrations of 1.5% or 2.5%, and
four dialysate exchanges per day. CAPD treatment schedules
and medications were not altered during the study. This
study was conducted in accordance with the Declaration
of Helsinki and was approved by the Institutional Ethical
Committee at the Akita City Hospital. Informed consent was
obtained from all patients.
Patient characteristics are shown in Table 1. Forty-four
patients who underwent a total of 58 angiographic CT
scans did not undergo HD treatment (the non-HD group),
and six patients who underwent six angiographic CT scans
underwent HD treatment (the immediate HD group).
2.1. Clearance Analysis of Iopamidol. Eleven patients were
enrolled for the clearance analysis of iopamidol. All CT
scans were performed for annual screening of renal cell
carcinoma caused by acquired cystic kidney disease. HD was
notperformedinanypatientafteriopamidoladministration.
Each patient received a 50mL/body (0.94 ± 0.21mL/kg)
intravenous bolus dose of iopamidol 300 (612.4mg/mL) for
angiographic CT. Blood samples were obtained from the 11
patients at the following times: 0.5, 1, 2, 3, 6, 12, 24, 36, 48,
72, and 96h after iopamidol administration. Total dialysate
and urine were collected every 24h for the 4 days following
administration. All samples were stored at −20◦C, and the
iopamidol concentrations in patient plasma, dialysate, and
urine were measured.
2.2. Iopamidol Concentration Assay. Samples were pretreated
with 0.5mol/L of perchloric acid, and, after centrifugation,
the supernatant was ﬁltered and measured. Iopamidol con-
centrations in plasma, dialysate, and urine were analyzed by
inductively coupled plasma atomic emission spectrometry
(SPS3000, Seiko Instruments Inc., Chiba, Japan).
2.3. Safety Analysis. For safety analysis, we observed patients
for adverse events, serum creatinine (Crea), estimated
glomerular ﬁltration rate (eGFR), and urine volume for 3
months after the angiographic CT scan.
2.4. Statistical Analysis. Statistical analyses were performed
using SPSS (SPSS Inc, ver. 12.0, Chicago, Ill, USA) and
Microsoft Excel (Microsoft Corporation, Redmond, Wash.,
USA) programs. All values included in the ﬁgures and text
a r ee x p r e s s e da sm e a n s± SD. Datasets were compared with
paired t test. A P value of <0.05 was considered signiﬁcant.International Journal of Nephrology 3
Table 2: Patient characteristics for clearance analysis of iopamidol.
Patients were divided into two groups based on their residual renal
function (RRF). RRF was deﬁned by a urine volume of more than
400mL/day. BMI: body mass index.
Clearance analysis All RRF (+) RRF (−)
n 11 2 9
Age 62.4 ±12.66 1 .0 ±13.66 8 .5 ±3.5
Gender (M/F) 6/5 1/1 5/4
Diabetes mellitus
(+/−) 5/6 1/1 4/5
Dialysis duration
(M) 57.8 ±23.36 4 .0 ±15.65 1 .4 ±25.2
Dialysate (L/day) 8.58 ±1.22 7.80 ±1.19 8.76 ±1.22
BMI 22.1 ±3.55 21.8 ±2.20 22.2 ±3.89
Crea (mg/dL) 9.80 ±2.66 7.40 ±1.41 10.3 ±2.61
eGFR
(mL/min/1.73m2) 4.56 ±1.03 5.61 ±0.10 4.32 ±0.99
Urine volume
(mL/day) 85.0 ±182 450 ±70.73 .89 ±7.82
Iopamidol
administration
(mL/body)
50.0 ±0.00 50.0 ±0.00 50.0 ±0.00
Plasma
elimination ratio
(%)∗
83.6 ±7.60 93.7 ±3.90 80.1 ±5.88
T1/2 (hours) 33.3 ±9.67 21.9 ±2.92 35.8 ±8.71
Dialysate
concentration∗ 0.10 ±0.04 0.06 ±0.01 0.11 ±0.04
∗at day 4.
We could not evaluate P values in Table 1 (n = 6) and 2
(n = 2), because the statistical power is insuﬃcient to detect
signiﬁcant diﬀerences in small numbers of patients.
3. Results
The characteristics of 11 patients in the clearance study
are shown in Table 2. The mean plasma concentration
versus time curve showed the mean iopamidol half-life
(T1/2) of 33.3 ± 9.67h (Figure 2(a)). The plasma iopamidol
elimination ratio was 83.6% ± 7.6% for 96h (Figure 2(b)).
The mean concentrations of iopamidol in dialysate and
urine are shown in Figures 2(c) and 2(d).I o p a m i d o lw a s
removed completely from dialysate and urine. Nine patients
suﬀeredfromanuriawithurinevolumelessthan20mL.Two
patients with urine volumes of >400mL were regarded as
having residual renal function (RRF).
Iopamidol clearance from the plasma of patients with
RRF (RRF (+)) and without RRF (RRF (−)) is illustrated in
Figures 3(a) and 3(b). Clearance from RRF (−) patients was
earlier on the ﬁrst day, but the elimination rate at day 4 was
delayed. The elimination rates of RRF (+) patients and RRF
(−) patients were 93.7% ± 3.90% and 80.1% ± 5.88% at day
4, respectively. The clearance T1/2 of iopamidol in RRF (+)
patients and RRF (−) patients were 21.9 ± 2.92h and 35.8
± 8.71h, respectively. Reﬂecting the plasma concentration
results, iopamidol concentrations in the dialysate of RRF
(−) patients were higher than those in RRF (+) patients at
day 4.
Results showing the incidence of adverse events, Crea,
eGFR, and urine volume after angiographic CT scans are
illustrated in Table 3. In the non-HD group, no acute or
delayed adverse events associated with iopamidol admin-
istration were observed in patients, regardless of whether
they were classiﬁed as RRF (+) or RRF (−). On the other
hand, of the six patients in the immediate HD group, two
patients showed adverse events; one had a skin disorder, and
the other had atrial ﬁbrillation. There were no diﬀerence in
Crea, eGFR, and urine volume after the angiographic CT
for 3 months in non-HD group, but we could not evaluate
statisticaldiﬀerenceinimmediateHDgroupbecauseofsmall
number of patients.
4. Discussion
Iopamidol is a nonionic water-soluble radiographic contrast
media with low osmolarity, low chemical toxicity, and
absence of ionic charge [14]. This sets it apart from other
available nonionic radiocontrast media, such as iomeprol,
iohexol, ioversol, iopentol, and iopromide. In our study, PD
eﬀectively removed iopamidol from the body, but iopamidol
elimination from patient plasma was remarkably prolonged
for more than 4 days. The clearance T1/2 and elimination
rates were comparable to previous reports; one reported
37.9h and 75.2%, and the other reported 32.6h and 84.4%
[7, 9]. Plasma iopamidol concentration and iopamidol in
CAPD dialysate were lower in RRF (−) patients at ﬁrst day.
However, at day 4, the elimination rates and the clearance
T1/2 of iopamidol in RRF (−) patients showed about 14%
and 14h delay compared with RRF (+) patients, respectively.
Although we could not conclude the eﬃcacy of RRF for the
elimination of radiocontrast media because of small number
of patients, these results suggest that renal excretion is an
important elimination pathway even in the end stage kidney.
This observation is consistent with the other recent studies
in CAPD patients [9].
We observed no signiﬁcant diﬀerence in Crea, eGFR,
and urine volume after the angiographic CT for 3 months
with or without RRF in non-HD group (Table 3). Although
eGFR is not suitable for evaluation of renal function in
dialysis patients, this suggests radiocontrast media has small
eﬀects on end-stage kidney. We could not evaluate statistical
diﬀerence because of small number of patients (n = 6) in
immediate HD group.
During the course of this study, there were no adverse
events in patients in the non-HD group, but two adverse
events were observed in the immediate HD group. This
suggests that the risk of adverse events due to iopamidol in
CAPD patients is low, indicating that the use of immediate
HD does not produce any beneﬁts. However, the mecha-
nisms and risks of related adverse events due to delayed
elimination of iopamidol are still not well known, and larger
studies are necessary to address the safety.
Donnelly et al. [7] reported a case of bilateral sub-
mandibular swelling possibly occurring 20h after the injec-
tion of iopamidol, which resolved over the next 7 days. One4 International Journal of Nephrology
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Figure2:Clearanceofiopamidol.Changesiniopamidolinpatientplasmaandclearanceofiopamidolresultingfromcontinuousambulatory
peritoneal dialysis (CAPD) are shown. Mean T1/2 of iopamidol was 33.3 ± 9.67h (a), and the plasma iopamidol elimination ratio was
83.6% ± 7.6% for 96h (b). Iopamidol was eliminated from patient dialysate (c) and patient urine (d) after 4 days.
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Figure 3: Iopamidol clearance with or without RRF. Clearance of iopamidol from the plasma of RRF (−) patients was earlier on the ﬁrst
day. However, the elimination rate at day 4 was signiﬁcantly delayed (a). At day 4, elimination rates of RRF (+) and RRF (−) patients
were 93.7% ± 3.90% and 80.1% ± 5.88%, respectively, and T1/2 of RRF (+) and RRF (−) patients were 21.9 ± 2.92 h and 35.8 ± 8.71h,
respectively. Dialysate iopamidol concentration in RRF (−) patients was higher than that of RRF (+) patients at day 4.International Journal of Nephrology 5
Table 3: Adverse events and residual renal function after angiographic CT scans. The incidence of adverse events, Crea, eGFR, and urine
volume for 3 months after angiographic CT scans is shown. Two patients showed adverse events within one day, in immediate HD group.
No adverse event was observed in non-HD group. Crea, eGFR, and urine volume were not diﬀerent before and after angiographic CT scans.
Statistical analysis in non-HD group was compared to baseline, 1, 2, and 3 months (paired t test).
non-HD RRF (+) Crea eGFR Urine vol. RRF (−) Crea eGFR Urine vol.
n 16 28
Angiographic CT (times) 19 39
Adverse event 0 0
Baseline 11.8 ±6.44 .97 ±2.47 442 ±424 11.2 ± 2.56 4.23 ±1.00 6.77 ± 29.3
1m o n t h 1 1 .5 ±4.35 .23 ±3.35 451 ±387 11.1 ± 2.53 4.28 ±0.96 11.6 ± 50.9
2m o n t h s 1 1 .3 ±3.74 .85 ±2.44 415 ±345 11.0 ± 2.26 4.27 ±0.88 3.71 ± 16.7
3m o n t h s 1 1 .3 ±3.74 .93 ±2.51 414 ±360 10.9 ± 2.30 4.33 ±0.96 8.67 ± 35.5
P value n.s. n.s. n.s. n.s. n.s. n.s.
Immediate HD RRF (+) Crea eGFR Urine vol. RRF (−) Crea eGFR Urine vol.
n 24
Angiographic CT (times) 2 4
Adverse event 1 1
Baseline 11.1 ±1.60 4.47 ±0.35 275 ±95.71 1 .6 ± 2.90 3.83 ±0.77 12.5 ± 28.0
1m o n t h 1 2 .9 ±4.60 3.97 ±1.15 175 ±177 11.8 ± 3.88 3.78 ±1.00 17.5 ± 28.7
2m o n t h s 1 2 .2 ±3.96 4.15 ±1.05 150 ±70.71 1 .9 ± 2.37 3.60 ±0.37 5.25 ± 6.08
3m o n t h s 1 2 .5 ±4.10 4.04 ±1.04 300 ±141 12.3 ± 2.09 3.45 ±0.42 6.25 ± 7.50
studyshowedthatconventional4-hHDtherapyimmediately
after the use of iodinated radiocontrast media eliminated
80% of the media and that this may reduce the possible
risks associated with delayed reactions [9, 15]. However,
our results suggest that immediate HD is not necessary
as there were no adverse events reported in the non-
HD group. Furthermore, there were negative reports about
the eﬀects of HD therapy immediately after the use of
iodinated radiocontrast media because it takes several HD
sessions to eliminate them completely [16, 17]. One report
suggested that 3 weeks are required to eliminate iodinated
radiocontrast media completely by CAPD in the regular
setting [17]. Frequent dialysate exchange with very short
cycles may more eﬀectively remove it from CAPD patients’
circulation [18]; however, it does not produce any beneﬁt.
This is due to slower peritoneal permeability of iodinated
radiocontrast media resulting from their high molecular
weight. Moreover, it is impracticable and increases the risk
of hypokalemia and hypovolemia [9]. These investigations
suggest a decreased necessity for scheduled HD or frequent
exchange of dialysate after the use of iodinated radiocontrast
media in CAPD patients because of a lower incidence ratio
of adverse events.
Because of insuﬃcient statistical power to detect signif-
icant diﬀerences in small number of patients, our results
cannot be generalized over the broader CAPD population.
Webelievethatourobservationswillservetoincreaseunder-
standing of the potential risks of iodinated radiocontrast
media and also assist further prospective studies to further
evaluate the eﬃcacy and safety in CAPD patients.
5. Conclusion
Our results suggest that iopamidol can be eliminated from
patients by regular CAPD schedules, and the incidence
of adverse events due to iopamidol in CAPD patients is
low. However, high levels of iodinated radiocontrast media
in the circulation may remain for several days, and this
may increase the general risk of adverse events. Adequate
preparation and careful observation for adverse events are
essential for the safe use of radiocontrast media.
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